Evidence map›Paper›PMID 34078669›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Mitochondria-dependent synthetic small-molecule vaccine adjuvants for influenza virus infection.

Fumi Sato-Kaneko, Shiyin Yao, Fitzgerald S Lao, Jason Nan, Jonathan Shpigelman, Annette Cheng, Tetsuya Saito, Karen Messer, Minya Pu, Nikunj M Shukla and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Progress towards Adjuvant Development: Focus on Antiviral Therapy.International journal of molecular sciences · 2023
    Review
  5. The role of autophagy in viral infections.Journal of biomedical science · 2023
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Fumi Sato-KanekoMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Shiyin YaoMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Fitzgerald S LaoMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Jason NanMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Jonathan ShpigelmanMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Annette ChengMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Tetsuya SaitoMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Karen MesserDepartment of Family Medicine and Public Health, University of California San Diego, La Jolla, CA 92093-0901.
Minya PuDepartment of Family Medicine and Public Health, University of California San Diego, La Jolla, CA 92093-0901.
Nikunj M ShuklaMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Howard B CottamMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Michael ChanMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809.
Anthony J MolinaDepartment of Medicine, University of California San Diego, La Jolla, CA 92093-0656.
Maripat CorrDepartment of Medicine, University of California San Diego, La Jolla, CA 92093-0656.
Tomoko HayashiMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809; thayashi@ucsd.edu dcarson@ucsd.edu.ORCID 0000-0002-9589-8348
Dennis A CarsonMoores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809; thayashi@ucsd.edu dcarson@ucsd.edu.ORCID 0000-0001-5273-0804
University of California San Diego · US

Funding

TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES.75N93019C00042 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARSON, DENNIS · 2019 to 2024
$10.2M
NIAID NIH HHS 75N93019C00042NIAID NIH HHS HHSN272201400051C
6 · The paper itself

Abstract

Vaccine adjuvants enhance and prolong pathogen-specific protective immune responses. Recent reports indicate that host factors-such as aging, pregnancy, and genetic polymorphisms-influence efficacies of vaccines adjuvanted with Toll-like receptor (TLR) or known pattern-recognition receptor (PRR) agonists. Although PRR independent adjuvants (e.g., oil-in-water emulsion and saponin) are emerging, these adjuvants induce some local and systemic reactogenicity. Hence, new TLR and PRR-independent adjuvants that provide greater potency alone or in combination without compromising safety are highly desired. Previous cell-based high-throughput screenings yielded a small molecule 81 [

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ViralDendritic CellsFemaleGene ExpressionHumansImmunity, InnateInfluenza, HumanInfluenza VaccinesLeukocytes, MononuclearMiceMice, Inbred BALB CMitochondriaOrthomyxoviridae InfectionsReactive Oxygen SpeciesAdjuvants, ImmunologicAntibodies, ViralInfluenza VaccinesReactive Oxygen SpeciesToll-Like Receptorsinfluenza virusmitochondrial reactive oxygen speciesmitochondrial stressNF-κBvaccine adjuvant

Identifiers

PMID34078669
PMCPMC8201894
OpenAlexW3164197304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.